PEspeaks

Mar 22, 2017
FDA efforts to speed more new generic drugs to market probably won’t do much to reduce high drug prices, writes Jill Wechsler.
Mar 17, 2017
It is hard to resist the sensation that the rhetoric of Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.
Mar 16, 2017
NICE and NHSE have been grappling with the issue of affordability. Leela Barham reports.
Mar 14, 2017
Trump’s choice for FDA commissioner faces drug pricing, regulatory, and approval challenges.
Mar 09, 2017
Pharmaceutical Executive
No longer just hype, investing in big data is the path to the future for pharma, even if big returns aren't a direct result, writes Pharm Exec Editor Lisa Henderson.
Mar 07, 2017
An FDA Memo addressing First Amendment legal issues regarding off-label use of medical products falls short of the necessary clarity, write Jamie Kendall and Alexandra Schulz.
Mar 01, 2017
President Trump calls for faster FDA approvals and lower drug prices. Jill Wechsler reports.
Feb 21, 2017
Neil Grubert discusses the key trends in market access this year and beyond.
Feb 10, 2017
In promising to expedite and simplify the FDA approval process, Donald Trump fails to take account of industry's appreciation an efficient, rigorous FDA regulatory system, writes Jill Wechsler.
Feb 08, 2017
Pharmaceutical Executive
Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.
native1_300x100
lorem ipsum